Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization

Clinical and Experimental Ophthalmology

Volumn 37, Issue 4, 2009, Pages 384-388

  Krishnan, Radhika ^a   Goverdhan, Srinivas ^a   Lochhead, Jonathan ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Bevacizumab; Choroidal neovascularization; Occult; Ranibizumab; Submacular haemorrhage

Indexed keywords

ANTICOAGULANT AGENT; BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; FEMALE; FISHER EXACT TEST; HUMAN; MALE; RETINA MACULA HEMORRHAGE; RETROSPECTIVE STUDY; SUBMACULAR HEMORRHAGE; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BLOOD PRESSURE; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; INCIDENCE; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; MALE; RETINAL HEMORRHAGE; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 67651180667     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2009.02043.x     Document Type: Article

References (13)

1. Chan CK, Meyer CH, Gross JG et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007; 27: 541-51.
2. Emerson MV, Lauer AK, Flaxel CJ et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27: 439-44.
3. Goverdhan SV, Lochhead J. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol 2008; 92: 210-12.
4. Poliner LS, Olk RJ, Burgess D, Gordon ME. Natural history of retinal pigment epithelial detachments in age-related macular degeneration. Ophthalmology 1986; 93: 543-51.
5. Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1-11.
6. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 2008; 22: 82-6.
7. Chieh JJ, Fekrat S. Large submacular haemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration. Ann Ophthalmol (Skokie) 2007; 39: 51-2.
8. Ronan SM, Yoganathan P, Chien FY et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 2007; 27: 535-40.
9. Carvounis PE, Kopel AC, Benz MS. Retinal pigment epithelium tears following ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol 2007; 143: 504-5.
10. Kiss C, Michels S, Prager F, Geitzenauer W, Schmidt-Erfurth U. Retinal pigment epithelium tears following intravitreal ranibizumab therapy. Acta Ophthalmol Scand 2007; 85: 902-3.
11. Pauleikhoff D, Löffert D, Spital G, Radermacher M, Dohrmann J, Lommatzsch A, Bird AC. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 2002; 240: 533-38.
12. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-59.
13. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179-82.